NCT02798536View on ClinicalTrials.gov

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 27, 2016

Primary Completion Date

July 20, 2017

Study Completion Date

April 21, 2022

Conditions
Mesothelioma
Interventions
DRUG

LMB-100

Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)

DRUG

nab-paclitaxel

Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02798536 - Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | Biotech Hunter | Biotech Hunter